Detail akcie COMPASS Path Sp ADR online

Business Summary: Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Compass Pathways PLC (ADR) revenues was not reported. Net loss increased 74% to $194M. Higher net loss reflects Pharmaceutical segment loss increase of 63% to $133.1M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.67 to -$2.06.